These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 17495322

  • 1. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
    Vanderkerken K, Medicherla S, Coulton L, De Raeve H, Willems A, Lawson M, Van Camp B, Protter AA, Higgins LS, Menu E, Croucher PI.
    Cancer Res; 2007 May 15; 67(10):4572-7. PubMed ID: 17495322
    [Abstract] [Full Text] [Related]

  • 2. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma.
    Medicherla S, Reddy M, Ying J, Navas TA, Li L, Nguyen AN, Kerr I, Hanjarappa N, Protter AA, Higgins LS.
    Anticancer Res; 2008 May 15; 28(6A):3827-33. PubMed ID: 19189670
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
    Nguyen AN, Stebbins EG, Henson M, O'Young G, Choi SJ, Quon D, Damm D, Reddy M, Ma JY, Haghnazari E, Kapoun AM, Medicherla S, Protter A, Schreiner GF, Kurihara N, Anderson J, Roodman GD, Navas TA, Higgins LS.
    Exp Cell Res; 2006 Jun 10; 312(10):1909-23. PubMed ID: 16600214
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
    Vanderkerken K, De Leenheer E, Shipman C, Asosingh K, Willems A, Van Camp B, Croucher P.
    Cancer Res; 2003 Jan 15; 63(2):287-9. PubMed ID: 12543775
    [Abstract] [Full Text] [Related]

  • 8. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
    Croucher PI, Shipman CM, Van Camp B, Vanderkerken K.
    Cancer; 2003 Feb 01; 97(3 Suppl):818-24. PubMed ID: 12548581
    [Abstract] [Full Text] [Related]

  • 9. Selection of a highly aggressive myeloma cell line by an altered bone microenvironment in the C57BL/KaLwRij mouse.
    Libouban H, Moreau MF, Baslé MF, Bataille R, Chappard D.
    Biochem Biophys Res Commun; 2004 Apr 09; 316(3):859-66. PubMed ID: 15033480
    [Abstract] [Full Text] [Related]

  • 10. Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.
    Van Valckenborgh E, Croucher PI, De Raeve H, Carron C, De Leenheer E, Blacher S, Devy L, Noël A, De Bruyne E, Asosingh K, Van Riet I, Van Camp B, Vanderkerken K.
    Am J Pathol; 2004 Sep 09; 165(3):869-78. PubMed ID: 15331411
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inhibition of p38alpha MAPK enhances proteasome inhibitor-induced apoptosis of myeloma cells by modulating Hsp27, Bcl-X(L), Mcl-1 and p53 levels in vitro and inhibits tumor growth in vivo.
    Navas TA, Nguyen AN, Hideshima T, Reddy M, Ma JY, Haghnazari E, Henson M, Stebbins EG, Kerr I, O'Young G, Kapoun AM, Chakravarty S, Mavunkel B, Perumattam J, Luedtke G, Dugar S, Medicherla S, Protter AA, Schreiner GF, Anderson KC, Higgins LS.
    Leukemia; 2006 Jun 09; 20(6):1017-27. PubMed ID: 16617327
    [Abstract] [Full Text] [Related]

  • 15. The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss.
    Böhm C, Hayer S, Kilian A, Zaiss MM, Finger S, Hess A, Engelke K, Kollias G, Krönke G, Zwerina J, Schett G, David JP.
    J Immunol; 2009 Nov 01; 183(9):5938-47. PubMed ID: 19828631
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Concomitant downregulation of proliferation/survival pathways dependent on FGF-R3, JAK2 and BCMA in human multiple myeloma cells by multi-kinase targeting.
    Cassinelli G, Ronchetti D, Laccabue D, Mattioli M, Cuccuru G, Favini E, Nicolini V, Greco A, Neri A, Zunino F, Lanzi C.
    Biochem Pharmacol; 2009 Nov 01; 78(9):1139-47. PubMed ID: 19555670
    [Abstract] [Full Text] [Related]

  • 19. Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
    Edwards CM, Mueller G, Roelofs AJ, Chantry A, Perry M, Russell RG, Van Camp B, Guyon-Gellin Y, Niesor EJ, Bentzen CL, Vanderkerken K, Croucher PI.
    Int J Cancer; 2007 Apr 15; 120(8):1657-63. PubMed ID: 17230522
    [Abstract] [Full Text] [Related]

  • 20. Absence of renal lesions in C57BL/KaLwRij mice with advanced myeloma due to 5T2MM cells.
    Libouban H, Onno C, Pascaretti-Grizon F, Gallois Y, Moreau MF, Baslé MF, Chappard D.
    Leuk Res; 2006 Nov 15; 30(11):1371-5. PubMed ID: 16814861
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.